TC
MYGN icon

Truvestments Capital’s Myriad Genetics MYGN Stock Holding History

Truvestments Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$89 – 1056
2025
Q1 		$89 Buy
+10
New +$120 ﹤0.01% 1004
2021
Q4 		– Sell
-67
Closed -$2K – 638
2021
Q3 		$2K Hold
67
– – ﹤0.01% 545
2021
Q2 		$2K Hold
67
– – ﹤0.01% 553
2021
Q1 		$2K Buy
+67
New +$1.9K ﹤0.01% 623

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Truvestments Capital's MYGN Position: Q2 2025 in Review

Truvestments Capital sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 10 shares — an estimated $89 sold.

Truvestments Capital first reported a position in MYGN in Q1 2021 and held it in 4 quarters. The position peaked at $2K in Q3 2021. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Truvestments Capital reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Truvestments Capital sold 10 Myriad Genetics shares in Q2 2025, an estimated $89.
  • Truvestments Capital first reported a position in Myriad Genetics in Q1 2021 and held it in 4 quarters.
  • Truvestments Capital's Myriad Genetics position peaked at $2K in Q3 2021.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Truvestments Capital's 13F filing for Q2 2025, filed 13 Aug 2025.